CinderBio

CinderBio is raising funds to commercialize our first enzyme products for clinical and research markets.

Technology:
CinderBio has developed and patented the world's first recombinant microbial platform using extremophilic Archaea that thrive in acidic hot springs in areas of volcanism around the world. We use our patented technologies to produce ultra-stable enzymes from our extremophilic microbes. Our unique enzymes enable new and sustainable applications and processes in many industries. Enzymes are catalysts that operate on biomolecules and are widely used in industries that require chemical transformations of biomolecules from foods/feeds biofuels and textiles to biological drug development and validation. CinderBio technologies have matured on federal funds, and we have a growing library of over a dozen ultra-stable industrial enzymes currently in production and have identified and successfully tested our enzymes for several large markets.

Markets:

Proteomics: We have soft- launched products into our beachhead market of proteomics on the heels of two seminal scientific publications following $1.6M in competitive funding from the National Institutes of Health. CinderBio's proprietary enzymes dramatically simplify sample preparation for proteomics and reduce preparation time from 18 hours to 5 minutes, and from nine steps to one step, enabling automation for the first time. We have active collaborations with leading proteomics groups in pharmaceutical and academic settings to refine our technologies and validate additional capabilities. CinderBio proteases bring entirely novel capabilities to proteomics field including including the most efficient QA/QC for biological drugs like antibodies. CinderBio is the only source for these enzymes and capabilities, and we find that we have unique access to a significant portion of the human proteome, with about one third of the human proteome being observable only with our technologies. Our technologies uniquely enable the detection and characterization of new disease markers and the development of practical clinical and diagnostic proteomics methods for early cancer detection, cardiovascular disease among others.

Cleaning & Sanitation: We have incubated our technologies with over $6M in competitive federal funding from the NSF, NIH, DOE, and were awarded a 2-year, $1M grant from the USDA in 2023 to apply our enzymes to cleaning and sanitation. Both the NSF and USDA efforts fund CinderBio to apply our unique enzymes to develop natural and non-toxic cleaning and sanitation methods for food processors and to displace harmful chemicals in our food supplies. We have run successful field trials at a local California creamery and had successful partnerships with Chobani and several chemical suppliers. Currently we are developing enzyme products for the meat and poultry industry and the food service industry as well as work with a leading biofuel company to improve their processes.

Alternative Protein: We have also developed and patented an economical method for producing hydrolysates (broken up proteins) from various feedstocks for use in foods and feeds. Hydrolysates are the costliest component of nutrients for cultured meats. CinderBio is staged to be a major supplier of these components and our proprietary technologies for the growing alternative proteins markets.

Other Markets: Because CinderBio makes the world’s most stable biocatalysts (enzymes), there are many other markets we intend to enter as we grow. We have produced and tested enzymes for Gen-1 and Gen-2 biofuels, textile applications, the alcoholic beverage industry, high fructose corn syrup, and several others.

Business: CinderBio is currently a lean startup staged to go to market and ready for growth. We have a rational growth strategy going from our laboratory reagents for proteomics, a low-volume high-margin market and progressing into higher volume markets as we build revenue and production capacity. We have over $1M of enzyme inventory for the proteomics market and have de-risked the scaling of our production and require only the capital for additional equipment to increase production capacity.
 
Team: CinderBio’s founder is a renowned scientist who started CinderBio based on his invention of CinderBio technologies in his lab in Berkeley and he has authored of all CinderBio grants, patents, and publications. He is joined by two seasoned business professionals who have both played leading roles in startups that ultimately went public. CinderBio’s patent strategy is advised by a retired senior partner from the respected Morrison Foerster firm who is currently a member of the Supreme Court Bar. Patent and business law are represented by top tier firms and talented attorneys.

We are seeking to fill a $4M equity seed round to build our business and sales teams and to grow towards our series A in the following 12-18 months. We have identified a lead investor and have a signed term sheet.

Ready to Ask For Funding for your company?

Post a Funding Request